{"id":"NCT01095835","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)","officialTitle":"A Multicenter, Randomized, Controlled Study Comparing the Efficacy and Safety of 48 Weeks of 40kD Branched Pegylated Interferon Alfa-2a (PEG-IFN, RO 25-8310) Versus 96 Weeks of PEG-IFN, Alone or in Combination With 100 mg Lamivudine for 48 Weeks in Patients With HBeAg-Negative Chronic Hepatitis B","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-02","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2010-03-30","resultsPosted":"2016-11-03","lastUpdate":"2016-11-03"},"enrollment":131,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis B, Chronic"],"interventions":[{"type":"DRUG","name":"Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg","otherNames":["Pegasys®"]},{"type":"DRUG","name":"Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg","otherNames":["Pegasys®"]},{"type":"DRUG","name":"Lamivudine (LAM)","otherNames":[]}],"arms":[{"label":"PEG-IFN48","type":"EXPERIMENTAL"},{"label":"PEG-IFN96","type":"EXPERIMENTAL"},{"label":"PEG-IFN+LAM96","type":"EXPERIMENTAL"}],"summary":"This study will compare the efficacy and safety of 2 different durations of treatment with pegylated interferon (PEG-IFN) alfa-2a in participants with Hepatitis B e Antigen (HBeAg)-negative chronic hepatitis B virus (HBV). It will also compare PEG-IFN alfa 2a treatment alone and in combination with lamivudine (LAM). The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period","timeFrame":"At the end of the 48-week follow-up period at Week 144","effectByArm":[{"arm":"PEG-IFN48","deltaMin":11.8,"sd":null},{"arm":"PEG-IFN96","deltaMin":25,"sd":null},{"arm":"PEG-IFN+LAM96","deltaMin":20,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.08"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":22,"countries":["Italy"]},"refs":{"pmids":["22859496"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":50},"commonTop":["Asthenia","Pyrexia","Headache","Neutropenia","Influenza like illness"]}}